Navigation Links
Cell Biosciences Launches Next-Generation Protein Characterization System

PALO ALTO, Calif., April 16 /PRNewswire/ -- Cell Biosciences, Inc., a provider of nanoproteomic analysis systems to life science researchers, today announced the launch of the Cell Biosciences CB1000 protein analysis system, a next-generation platform for ultrasensitive characterization of cell signaling proteins. The CB1000 establishes a new standard for sensitivity, reproducibility, and ease-of-use for researchers studying signaling pathways in limited samples, such as small tumor biopsies and stem cells. The CB1000 will be unveiled at the American Association for Cancer Research (AACR) 100th Annual Meeting, April 18-22, 2009, in Denver, Colorado (booth 2039).

The CB1000 system measures phosphorylation events and other protein post-translational modifications using capillary-based nanofluidic immunoassays, and builds upon the fundamental technology of its predecessor, the Firefly(TM) 3000 system. The advanced design of the CB1000 system provides significant improvements in assay performance and automation, including a doubling of sample throughput. Assay reproducibility and stability have been increased through the incorporation of precise temperature control systems. In addition, the CB1000's software package, Compass(TM), features dramatic improvements in data analysis speed.

David Hirschberg, Ph.D., Director of the Human Immune Monitoring Center at Stanford University School of Medicine, recently completed a three-month evaluation of a prototype CB1000 system. "This system represents an impressive step forward for Cell Biosciences' technology," noted Dr. Hirschberg. "My group has been using the CB1000 system heavily - typically six days a week. We have been extremely pleased by the system's high level of performance and reliability."

"The CB1000 is our first platform designed for broad distribution," added Tim Harkness, President and Chief Executive Officer at Cell Biosciences. "We believe that the CB1000 will allow us to penetrate important new markets as we build our worldwide commercial infrastructure. We also believe that the CB1000 will enable our customers to gain novel insights into the causes and treatment of human disease."

About Cell Biosciences

Cell Biosciences is a private life sciences company focused on nanoproteomics. We develop instrumentation systems, software, and assay products that reveal previously undetectable information about cellular control pathways. Our customers include leading institutions in the fields of cancer research, stem cell biology, and diabetes. Our products enable researchers to uncover fundamental mechanisms controlling cell proliferation and cell death, to accelerate the development of new therapeutics, and to help identify new prognostic and diagnostic disease biomarkers. Cell Biosciences is located in Palo Alto, California. For more information, visit

SOURCE Cell Biosciences, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Cell Biosciences Announces Publication in Nature Medicine
2. Cell Biosciences Closes $10 Million Series C Financing
3. SAFC Biosciences(R) Expands Media Capability for Chinese Hamster Ovary (CHO) Cell Lines
4. SAFC Biosciences(TM) Completes Conversion of Lenexa Media Milling Facility to Animal Component Free
5. Neurocrine Biosciences to Present at the 16th Annual Future Leaders in the Biotech Industry Conference
6. Catalyst Biosciences Expands Scientific Advisory Board With Leading Experts in Protease Therapeutic Discovery and Development
7. WaferGen Biosystems, ImmuneRegen BioSciences and University of Texas Southwestern Medical Center to Collaborate on Novel Wound Healing Research
8. Neurocrine Biosciences to Present at the Cowen and Company 29th Annual Health Care Conference
9. Pressure BioSciences, Inc. Reports Record Revenue, Significantly Reduced Operating Loss for the Fourth Quarter of 2008
10. Pressure BioSciences, Inc. to Present at the EdgeWater Research Partners Spring 2009 Micro/Small-Cap Investor Conference
11. Speid & Associates Partners With Genizon BioSciences to Reduce Attrition Rates of New Drug Compounds
Post Your Comments:
(Date:11/24/2015)... November 24, 2015 --> ... research report "Oligonucleotide Synthesis Market by Product & Services ... Synthesis, Diagnostic, DNA, RNAi), End-User (Research, Pharmaceutical & Biotech, ... MarketsandMarkets, the market is expected to reach USD 1,918.6 ... at a CAGR of 10.1% during the forecast period. ...
(Date:11/24/2015)... ... ... The Academy of Model Aeronautics (AMA), led by its Executive Council, has officially ... to represent the First–Person View (FPV) racing community. , FPV racing has exploded in ... racing and several new model aviation pilots have joined the community because of their ...
(Date:11/24/2015)... ALBANY, New York , November 24, 2015 /PRNewswire/ ... According to a recent market research report released by ... is projected to expand at a CAGR of 17.5% ... titled "Non-invasive Prenatal Testing Market - Global Industry Analysis, ... 2022", estimates the global non-invasive prenatal testing market to ...
(Date:11/24/2015)... Nov. 24, 2015 /PRNewswire/ - Aeterna Zentaris Inc. ... that the remaining 11,000 post-share consolidation (or 1,100,000 ... (the "Series B Warrants") subject to the previously ... November 23, 2015, which will result in the ... effect to the issuance of such shares, there ...
Breaking Biology Technology:
(Date:11/10/2015)... NEW YORK , Nov. 10, 2015 /PRNewswire/ ... refers to behavioral biometrics that helps to identify ... prevent fraud. Signature is considered as the secure ... for the identification of a particular individual because ... offers more accurate results especially when dynamic signature ...
(Date:11/9/2015)... Calif. , Nov. 9, 2015  Synaptics Inc. ... interface solutions, today announced broader entry into the automotive ... solutions that match the pace of consumer electronics human ... biometric sensors are ideal for the automotive industry and ... Europe , ...
(Date:11/2/2015)... , Nov. 2, 2015  SRI International has been ... provide preclinical development services to the National Cancer Institute ... will provide scientific expertise, modern testing and support facilities, ... preclinical pharmacology and toxicology studies to evaluate potential cancer ... The PREVENT Cancer Drug Development Program is an ...
Breaking Biology News(10 mins):